A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

What Was Tested

In this phase 2 trial, researchers set out to test Semaglutide.

Participants will get either NNC0662-0419, semaglutide or placebo.

It had three arms (groups): NNC0662-0419 (experimental), Semaglutide (active comparator) and Placebo (placebo comparator).

Participants will receive semaglutide s.c. once weekly.

Participants will receive placebo matched to their respective investigational medicinal product s.c. once weekly.

The registry classes the interventions as drug.

Who Took Part

270 planned participants were the target.

It was open to people of any sex aged from 18 years up to 75 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

The full record lists 4 inclusion and 3 exclusion criteria; among the exclusions: known hypoglycaemic unawareness as indicated by the investigator according to clarke's questionnaire.

How the Study Was Run

It was run as a randomized, parallel-group and quadruple-blind study.

Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Blinding on both sides kept the participants and researchers unaware of who received Semaglutide.

Those kept unaware of assignments: participant, care provider, investigator and outcomes assessor.

It started in 2026-04-17 with completion listed for 2027-09-03.

It ran at 63 sites in United States (23), Spain (6), Japan (5), Poland (5), Thailand (5) and Croatia (4).

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Change in glycated haemoglobin (HbA1c) (week 16) (time frame: From baseline (week 0) to week 16). Change in HbA1c (week 28) (time frame: From baseline (week 0) to week 28). Change in HbA1c (week 40) (time frame: From baseline (week 0) to week 40).

It also tracked 14 secondary outcomes, for example Relative change in body weight, Change in body weight, Change in HbA1c, Change in Fasting Plasma Glucose (FPG), Change in Body Mass Index (BMI) and Change in waist circumference.

What This Means in Plain Language

Put simply, this is a phase 2, randomized trial of Semaglutide in 270 people.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.